Nuvalent, Inc.
NUVL
Updated: 23/09/2026, 07:04:39
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
No summaries found.
- Share price
- $123.96
- Market cap
- $9.13B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- James R. Porter
- Employees
- 234
- IPO date
- 29/07/2021
- Beta
- 1.138
- Last dividend
- $0.00
- Day range
- $123.96 – $123.96
- 52-week range
- $71.13 – $123.99
- 1-day performance
- 0.00%
- 1-year performance
- 74.27%
- Current drawdown (1Y)
- -0.02%
- CIK
- 0001861560
- CUSIP
- 670703107
- ISIN
- US6707031075
- Created
- 07/12/2025, 05:31:48
- Last update
- 23/09/2026, 07:04:39
Track Nuvalent, Inc. with an AI analyst
See which prediction-market events move NUVL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nuvalent Acquisition: GSK's Strategic Move in Cancer Treatment and Market Reaction
Market Data • Market Data • 09/06/2026, 18:13:24
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
Schaeffers Research • STOCK • 09/06/2026, 11:12:37
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
PRNewsWire • STOCK • 27/05/2026, 08:30:00
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
PRNewsWire • STOCK • 21/05/2026, 19:23:00
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
PRNewsWire • STOCK • 07/05/2026, 08:30:00
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal
Seeking Alpha • STOCK • 30/04/2026, 16:22:44
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
PRNewsWire • STOCK • 21/04/2026, 12:32:00
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
PRNewsWire • STOCK • 17/04/2026, 18:01:00
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
PRNewsWire • STOCK • 07/04/2026, 08:30:00
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
PRNewsWire • STOCK • 17/03/2026, 18:15:00
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
The Motley Fool • STOCK • 16/03/2026, 21:00:55
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?
Zacks Investment Research • STOCK • 27/02/2026, 11:55:32